All In Biotech

Drug Trial Radar · NCT06939283

A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma

A Phase 1b/2 Multisite Dose- and Regimen-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma (NHL)

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Apr 21, 2025

Primary completion

Apr 23, 2026

Study completion Apr 23, 2026

Sponsor

Lead sponsor
Werewolf Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Apr 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety and tolerability of the study drug WTX-330 when administered using a fixed dose regimen or a step-up dose regimen in adult patients with selected advanced or metastatic solid tumors or lymphoma. In addition to safety and tolerability, the study aims to: * determine the maximum initial dose of WTX-330 that may be used in the step-up dose regimen * determine whether the step-up dose regimen can increase WTX-330 exposure in patients due to improved tolerability * determine the maximum tolerated dose (MTD) of WTX-330 and/or recommended dose for expansion (RDE) for each regimen * evaluate the antitumor activity of WTX-330 * characterize the pharmacokinetic (PK) profile of WTX-330 * characterize the interferon gamma (IFNγ) profile after treatment with WTX-330 * evaluate changes in immunological biomarkers * determine the impact of WTX-330 on overall survival (OS) Study participants will participate in a dose- and regimen-finding phase (Part 1) followed by a dose expansion phase (Part 2) where they will be assigned to one of three arms (A, B and C).

Conditions

  • Advanced or Metastatic Solid Tumors
  • Non-Hodgkin Lymphoma

Interventions

  • WTX-330Drug

    Investigational Product

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose Limiting Toxicities (DLTs)Time frame: 4 weeks
  2. Incidence of treatment emergent adverse eventsTime frame: 24 months
  3. Incidence of changes in clinical laboratory abnormalitiesTime frame: 24 months
  4. Overall response rate (ORR) by response evaluation criteria in solid tumors (RECIST) 1.1 and the immune-overall response rate (iORR) by immune RECIST (iRECIST; Part 2, Arms A and B) or response by Lugano classification (Part 2, Arm C)Time frame: 24 months
  5. Duration of response (DOR) by response evaluation criteria in solid tumors (RECIST) 1.1 and immune RECIST (iRECIST; Part 2, Arms A and B) or based on Lugano classification (Part 2, Arm C)Time frame: 24 months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • HonorHealth Research Institute

    Scottsdale, Arizona

  • Emory Winship Cancer Institute

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    Indianapolis, Indiana

  • NEXT Oncology

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.